In this population, 53% of individuals had commercial health insurance, 18% had Medicare, 11% had Medicaid, 1% had Dual (Medicare/Medicaid) coverage, and 17% had other coverage (e.g., Tricare, Veterans Affairs, or other State or local programs)
The STEP 1 extension data When semaglutide treatment was discontinued in the STEP 1 trial extension, participants regained approximately two-thirds of the weight they had lost within one year of stopping
"Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes." (STEP 8) JAMA
10.1053/j.jrn.2018.05.007 80 PoesenR.EvenepoelP.de LoorH.BammensB.ClaesK.SprangersB.et al (2016)
What should I do if Ozempic isn't reducing my appetite
Kinzig et al., 2002